Recent Trials in Hypertension
- 12 April 2006
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 295 (14) , 1704-1706
- https://doi.org/10.1001/jama.295.14.1704
Abstract
With rare exceptions, hypertension is an asymptomatic risk factor for cardiovascular events such as myocardial infarction, stroke, and heart failure. In contrasKeywords
This publication has 9 references indexed in Scilit:
- Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysisThe Lancet, 2005
- Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysisThe Lancet, 2005
- The PROactive study: some answers, many questionsThe Lancet, 2005
- Atenolol in hypertension: is it a wise choice?The Lancet, 2004
- A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the international verapamil-trandolapril study (INVEST): a randomized controlled trialACC Current Journal Review, 2004
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 ReportJAMA, 2003
- A Comparison of Outcomes with Angiotensin-Converting–Enzyme Inhibitors and Diuretics for Hypertension in the ElderlyNew England Journal of Medicine, 2003
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololPublished by Elsevier ,2002
- The Relative Risk of Incident Coronary Heart Disease Associated With Recently Stopping the Use of β-BlockersJAMA, 1990